Publication | Open Access
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody
267
Citations
33
References
2012
Year
VaccinationInfluenza HaImmunologyMolecular BiologyVirologyStrain SelectionAntibody EngineeringTrivalent VaccineAffinity MaturationInfluenza VaccineViral Structural ProteinAntigen-binding SiteMedicineFlu VaccinationViral Immunity
Affinity maturation refines a naive B‑cell response by selecting mutations in antibody variable domains that enhance antigen binding. The study describes a B‑cell lineage expressing broadly neutralizing influenza virus antibodies derived from a subject immunized with the 2007 trivalent vaccine. The authors analyzed antibody sequences from that subject to identify the lineage expressing broadly neutralizing influenza virus antibodies. The lineage, comprising three mature antibodies, an unmutated ancestor, and an intermediate, shows that heavy‑chain CDR insertion into the conserved HA pocket and rigidification via two independent pathways account for most affinity gain, informing broadly effective influenza vaccine design.
Affinity maturation refines a naive B-cell response by selecting mutations in antibody variable domains that enhance antigen binding. We describe a B-cell lineage expressing broadly neutralizing influenza virus antibodies derived from a subject immunized with the 2007 trivalent vaccine. The lineage comprises three mature antibodies, the unmutated common ancestor, and a common intermediate. Their heavy-chain complementarity determining region inserts into the conserved receptor-binding pocket of influenza HA. We show by analysis of structures, binding kinetics and long time-scale molecular dynamics simulations that antibody evolution in this lineage has rigidified the initially flexible heavy-chain complementarity determining region by two nearly independent pathways and that this preconfiguration accounts for most of the affinity gain. The results advance our understanding of strategies for developing more broadly effective influenza vaccines.
| Year | Citations | |
|---|---|---|
Page 1
Page 1